Canada’s biotech sector may finally be on the road to a sustained recovery after a series of short-lived remissions. A number of long-awaited projects are almost ready to bear fruit as a handful of companies get ready to introduce new drugs while others are weeks away from pivotal trial results. About 30 Canadian biotechs have products in the pipeline, according to Martin Garand, assistant vice president of global equity research at TAL Global Asset Management Inc.
